Membrane oxygenator longevity was higher in Argatroban treated patients undergoing vvECMO.

Loredana MenningerAndreas KörnerValbona MirakajKa-Lin Heck-SwainHelene A HaeberleKarina AlthausMichael BaumgartnerWalter JostChristian SchlensakPeter RosenbergerMichael Koeppen

Published in: European journal of clinical investigation (2023)

Our findings suggest that argatroban can be considered as anticoagulant during vvECMO.

Keyphrases

patients undergoing
atrial fibrillation
venous thromboembolism
drosophila melanogaster
newly diagnosed